GlobeNewswire Inc | May 11, 2021 08:00AM EDT

May 11, 2021

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Tuesday, May 18 at 8:00 a.m. ET.

The live webcast of the presentation will be available on the Investors page of the Company's website. An archived presentation will be available on the Merus website for a limited time.

About MerusMerus is a clinical-stage oncology company developing innovative full-length human bispecific andtrispecific antibody therapeutics, referred to as Multiclonics. Multiclonics are manufactured usingindustry standard processes and have been observed in preclinical and clinical studies to have several ofthe same features of conventional human monoclonal antibodies, such as long half-life and lowimmunogenicity. For additional information, please visit Merus website and twitter.

Investor and Media Inquiries:

Kathleen FarrenMerus N.V.Communications Specialist617-230-4165k.farren@merus.nl